Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC J9380
    Short Description Inj teclistamab cqyv 0.5 mg
    Long Description Injection, teclistamab-cqyv, 0.5 mg
    Pricing indicator 51
    Coverage code C
    ASC payment group code YY
    BETOS2 code O1E
    Action code N
    Type of service 1
    Effective date 2023-07-01
    Date Added 2023-07-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    57894044901 J9380 Inj teclistamab cqyv 0.5 mg TECVAYLI Janssen Biotech, Inc. 0.5 MG 3 1 60 60
    57894045001 J9380 Inj teclistamab cqyv 0.5 mg TECVAYLI Janssen Biotech, Inc. 0.5 MG 1.7 1 306 306
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    Drug Details

    • Teclistamab-cqyv injection is used to treat multiple myeloma (a type of cancer of the bone marrow) that has returned or has not improved in adults who have received at least 4 other medications. Teclistamab-cqyv is in a class of medications bispecific T-cell engager antibodies. It works by killing cancer cells.